Sign up to save your podcasts
Or
Share Sanjay Srivastava: Are CGTs Developing into a Commercial Dead-End?
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Sanjay Srivastava: Are CGTs Developing into a Commercial Dead-End?
In this episode of the Ori Spotlight Podcast, we're joined by Sanjay Srivastava, Managing Director of Accenture's Cell and Gene Therapy Practice. With his extensive background in consulting and a deep understanding of the biotechnology sector, Sanjay offers unique insights into the rapidly evolving world of cell and gene therapies.
Sanjay and Jason C. Foster delve into the critical challenges facing the industry, particularly focusing on the scalability and efficiency of manufacturing processes. They discuss how these challenges impact the commercial viability of advanced therapies and the necessity of adapting our current healthcare systems to better accommodate innovative treatments.
Learn more about Sanjay here: https://www.linkedin.com/in/nitreniumions/
View all episodes
By Ori BiotechIn this episode of the Ori Spotlight Podcast, we're joined by Sanjay Srivastava, Managing Director of Accenture's Cell and Gene Therapy Practice. With his extensive background in consulting and a deep understanding of the biotechnology sector, Sanjay offers unique insights into the rapidly evolving world of cell and gene therapies.
Sanjay and Jason C. Foster delve into the critical challenges facing the industry, particularly focusing on the scalability and efficiency of manufacturing processes. They discuss how these challenges impact the commercial viability of advanced therapies and the necessity of adapting our current healthcare systems to better accommodate innovative treatments.
Learn more about Sanjay here: https://www.linkedin.com/in/nitreniumions/
More shows like Ori Spotlight
View all
Biotech Hangout
17 Listeners